Literature DB >> 20546699

Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.

Michael W Otto1, R Kathryn McHugh, Naomi M Simon, Frank J Farach, John J Worthington, Mark H Pollack.   

Abstract

Despite its acute efficacy for the treatment of panic disorder, benzodiazepines (BZs) are associated with a withdrawal syndrome that closely mimics anxiety sensations, leading to difficulty with treatment discontinuation and often disorder relapse. An exposure-based cognitive-behavioral treatment for BZ discontinuation, Panic Control Treatment for BZ Discontinuation (CBT) targets the fear of these sensations and has demonstrated efficacy in preventing disorder relapse and facilitating successful BZ discontinuation among patients with panic disorder. In this randomized controlled trial, CBT was compared to taper alone and a taper plus a relaxation condition to control for the effect of therapist contact and support among 47 patients with panic disorder seeking taper from BZs. Based on the primary outcome of successful discontinuation of BZ use, results indicate that adjunctive CBT provided additive benefits above both taper alone and taper plus relaxation, with consistently medium and large effect sizes over time that reached significance at the six month follow-up evaluation. The efficacy of CBT relative to either of the other taper conditions reflected very large and significant effect sizes at that time. These findings suggest that CBT provides specific efficacy for the successful discontinuation from BZs, even when controlling for therapist contact and relaxation training. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20546699      PMCID: PMC5962448          DOI: 10.1016/j.brat.2010.04.002

Source DB:  PubMed          Journal:  Behav Res Ther        ISSN: 0005-7967


  36 in total

Review 1.  Strategies for discontinuing long-term benzodiazepine use: meta-analysis.

Authors:  Richard C Oude Voshaar; Jaap E Couvée; Anton J L M van Balkom; Paul G H Mulder; Frans G Zitman
Journal:  Br J Psychiatry       Date:  2006-09       Impact factor: 9.319

2.  An inventory for measuring clinical anxiety: psychometric properties.

Authors:  A T Beck; N Epstein; G Brown; R A Steer
Journal:  J Consult Clin Psychol       Date:  1988-12

3.  Internal consistencies of the original and revised Beck Depression Inventory.

Authors:  A T Beck; R A Steer
Journal:  J Clin Psychol       Date:  1984-11

Review 4.  Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy.

Authors:  M W Otto; J J Hong; S A Safren
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

5.  Dismantling cognitive-behavioral treatment for panic disorder: questioning the utility of breathing retraining.

Authors:  N B Schmidt; K Woolaway-Bickel; J Trakowski; H Santiago; J Storey; M Koselka; J Cook
Journal:  J Consult Clin Psychol       Date:  2000-06

6.  Empirically supported treatments for panic disorder: costs, benefits, and stepped care.

Authors:  M W Otto; M H Pollack; K M Maki
Journal:  J Consult Clin Psychol       Date:  2000-08

7.  An experimental investigation of the role of safety-seeking behaviours in the maintenance of panic disorder with agoraphobia.

Authors:  P M Salkovskis; D M Clark; A Hackmann; A Wells; M G Gelder
Journal:  Behav Res Ther       Date:  1999-06

8.  Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome.

Authors:  E Schweizer; K Rickels; W G Case; D J Greenblatt
Journal:  Arch Gen Psychiatry       Date:  1991-05

9.  Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder.

Authors:  M W Otto; M H Pollack; G S Sachs; S R Reiter; S Meltzer-Brody; J F Rosenbaum
Journal:  Am J Psychiatry       Date:  1993-10       Impact factor: 18.112

Review 10.  Benzodiazepine withdrawal: overview and implications for the treatment of anxiety.

Authors:  P P Roy-Byrne; D Hommer
Journal:  Am J Med       Date:  1988-06       Impact factor: 4.965

View more
  20 in total

1.  A randomized, controlled trial of the efficacy of an interoceptive exposure-based CBT for treatment-refractory outpatients with opioid dependence.

Authors:  Michael W Otto; Bridget A Hearon; R Kathryn McHugh; Amanda W Calkins; Elizabeth Pratt; Heather W Murray; Steven A Safren; Mark H Pollack
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

2.  Unified protocol for the discontinuation of long-term serotonin reuptake inhibitors in obsessive compulsive disorder: Study protocol and methods.

Authors:  Christina L Boisseau; Steven A Rasmussen
Journal:  Contemp Clin Trials       Date:  2018-01-03       Impact factor: 2.226

Review 3.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

4.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

Review 5.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

Review 6.  Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorder.

Authors:  Amy L Mahan; Kerry J Ressler
Journal:  Trends Neurosci       Date:  2011-07-26       Impact factor: 13.837

Review 7.  From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders.

Authors:  Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin
Journal:  Neurobiol Learn Mem       Date:  2013-12-07       Impact factor: 2.877

8.  Anxiety sensitivity and nonmedical benzodiazepine use among adults with opioid use disorder.

Authors:  R Kathryn McHugh; Victoria R Votaw; Olivera Bogunovic; Sterling L Karakula; Margaret L Griffin; Roger D Weiss
Journal:  Addict Behav       Date:  2016-08-18       Impact factor: 3.913

9.  Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.

Authors:  Zev Schuman-Olivier; Bettina B Hoeppner; Roger D Weiss; Jacob Borodovsky; Howard J Shaffer; Mark J Albanese
Journal:  Drug Alcohol Depend       Date:  2013-05-18       Impact factor: 4.492

Review 10.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.